Characterized by small, highly heterogeneous patient populations, rare disease trials
magnify the challenges often encountered in traditional clinical trials. In recent years, there have
been increased efforts by stakeholders to improve drug development in rare diseases through novel
approaches to clinical trial designs and statistical analyses. We highlight and discuss some of the
current and emerging approaches aimed at overcoming challenges in rare disease clinical trials,
with a focus on the ultimate stakeholder, the patient.